Alvotech (NASDAQ:ALVO) Sees Large Volume Increase – What’s Next?

Alvotech (NASDAQ:ALVO) shares saw unusually-strong trading volume on Monday . Approximately 731,636 shares traded hands during trading, an increase of 43% from the previous session’s volume of 511,028 shares.The stock last traded at $4.0380 and had previously closed at $3.54.

Analyst Ratings Changes

A number of analysts have commented on ALVO shares. Barclays lowered their price target on Alvotech from $5.00 to $4.00 and set an “underweight” rating for the company in a research report on Tuesday, March 24th. Weiss Ratings raised Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Wall Street Zen cut Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Zacks Research raised Alvotech from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 19th. Finally, UBS Group decreased their price objective on Alvotech from $10.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.60.

Alvotech Stock Performance

The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -16.42 and a beta of 0.21. The firm’s 50 day moving average is $3.44 and its 200-day moving average is $4.27.

Alvotech (NASDAQ:ALVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.09) earnings per share for the quarter. Alvotech had a negative return on equity of 11.92% and a negative net margin of 14.36%.The firm had revenue of $105.90 million during the quarter. As a group, sell-side analysts forecast that Alvotech will post 0.02 earnings per share for the current year.

Institutional Trading of Alvotech

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its position in shares of Alvotech by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 36,444 shares of the company’s stock valued at $352,000 after buying an additional 10,573 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Alvotech by 0.7% in the second quarter. Geode Capital Management LLC now owns 230,291 shares of the company’s stock valued at $2,100,000 after buying an additional 1,574 shares in the last quarter. Invesco Ltd. increased its position in shares of Alvotech by 37.3% in the second quarter. Invesco Ltd. now owns 32,398 shares of the company’s stock valued at $295,000 after buying an additional 8,794 shares in the last quarter. Bank of America Corp DE increased its position in shares of Alvotech by 218.0% in the second quarter. Bank of America Corp DE now owns 16,623 shares of the company’s stock valued at $152,000 after buying an additional 11,395 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of Alvotech in the second quarter valued at approximately $1,782,000.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high?quality, cost?effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in?house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).